HIGH DOSE SEQUENTIALCHEMOTHERAPY WITH RITUXIMAB AND ASCT AS FIRST LINE THERAPY IN ADULT MCL PATIENTS: CLINICAL AND MOLECULARRESPONSE OF THE MCL0208 TRIAL, A FIL STUDY

被引：0
|
作者：
Cortelazzo, S. [1 ]
Martelli, M. [2 ]
Ladetto, M. [3 ]
Ferrero, S. [4 ]
Ciccone, G. [5 ]
Evangelista, A. [5 ]
Mian, M. [6 ]
Di Rocco, A. [2 ]
Chiappella, A. [7 ]
Rossi, G. [8 ]
Re, A. [9 ]
Zinzani, P. L. [10 ]
Balzarotti, M. [11 ]
Cavallo, F. [4 ]
Rusconi, C. [12 ]
Gotti, M. [13 ]
Arcaini, L. [13 ]
Gobbi, M. [14 ]
Gomes, M. [15 ]
Molinari, A. [16 ]
Liberati, A. M. [17 ]
Michieli, M. [18 ]
Latte, G. [19 ,20 ]
Cabras, M. G. [21 ]
Novero, D. [22 ]
Paulli, M. [23 ]
Zamo, A. [24 ,25 ]
Chilosi, M. [24 ,25 ]
Federico, M. [26 ]
Vitolo, U. [7 ]
机构：
[1] Ist Clin Humanitas Gavazzeni, Unita Oncol Med & Ematol, Hematol, Bergamo, Italy
[2] Univ Roma La Sapienza, Dip Biotecnol Cellulari & Ematol, Hematol, I-00185 Rome, Italy
[3] AO SS Antonio & Biagio, SC Ematol, Hermatol, Alessandria, Italy
[4] SCDU Ematol Univ, AO Citta Salute & Sci, Hematol, Turin, Italy
[5] AO Citta Salute & Sci, CPO Piemonte Ctr Riferimento Epidemiol & Prevenz, Epidemiol, Turin, Italy
[6] Med Univ Innsbruck, Dept Hematol & Oncol, Hematol, A-6020 Innsbruck, Austria
[7] AO Citta Salute & Sci, SC Ematol, Hematol, Turin, Italy
[8] Spedali Civil Brescia, SC Ematol, Hematol, I-25125 Brescia, Italy
[9] Spedali Civil Brescia, SC Ematol, Hermatol, I-25125 Brescia, Italy
[10] St Orsola Marcello Malpighi Hosp, Ist Ematol & Oncol Med Seragnoli, Hematol, Bologna, Italy
[11] Ist Clin Human, Hematol Oncol Med & Ematol, Rozzano, Italy
[12] Osped Maggiore Niguarda, Div Ematol, Hematol, Milan, Italy
[13] Fdn IRCCS Policlin San Matteo, Dipartimento Ematol Oncol, Hematol, Pavia, Italy
[14] IRCCS AOU San Martino IST, Clin Ematol, Hematol, Genoa, Italy
[15] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Hematol, Lisbon, Portugal
[16] Osped Infermi, UO Ematol, Hematol, Rimini, Italy
[17] Osped Santa Maria, Struttura Complessa Oncoematol, Hematol, Terni, Italy
[18] Med A Ctr Riferimento Oncol, Oncol, Aviano, Italy
[19] UOC Ematol, Hematol, Nuoro, Italy
[20] CTMO Presidio Osped S Francesco, Nuoro, Italy
[21] Osped Businco, Div Ematol, Hematol, Cagliari, Italy
[22] AO Citta Salute & Sci, Anat Patol, Pathol, Turin, Italy
[23] Dipartimento Sci Pediat & Patol Umana, Sez Anat Patol, Pathol, Pavia, Italy
[24] Univ Verona, Dipartimento Patol & Diagnost, Pathol, I-37100 Verona, Italy
[25] AOUI Verona, Verona, Italy
[26] Univ Modena & Reggio Emilia, Policlin, COM Ctr Oncol Modenese, Oncol,Dipartimento Oncol & Ematol, Modena, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S106
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [41] Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma
    Massaro, Fulvio
    Stepanishyna, Yana
    Manni, Martina
    Luminari, Stefano
    Galimberti, Sara
    Marcheselli, Luigi
    Visco, Carlo
    Tecchio, Cristina
    Stelitano, Caterina
    Angrilli, Francesco
    Petrini, Mario
    Merli, Francesco
    Federico, Massimo
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (06) : 1011 - 1014
  • [42] Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune Thrombocytopenia
    Hu Zhou
    Liu Liu
    Xinhui Shu
    Xiaoran Wang
    Yongping Song
    Indian Journal of Hematology and Blood Transfusion, 2019, 35 : 507 - 512
  • [43] Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune Thrombocytopenia
    Zhou, Hu
    Liu, Liu
    Shu, Xinhui
    Wang, Xiaoran
    Song, Yongping
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2019, 35 (03) : 507 - 512
  • [44] High-dose therapy and autologous peripheral blood stem transplantation (ABSCT) during first remission in patients (PTS) with advanced stages and poor-prognosis mantle cell lymphoma (MCL)
    Nademanee, A
    Molina, A
    Smith, E
    Stein, A
    Planas, I
    Vora, N
    Forman, SJ
    BLOOD, 1996, 88 (10) : 474 - 474
  • [45] HyperCVAD-MA-R followed by autologous SCT as the first line therapy for MCL (mantle cell lymphoma) patients - Multi-center PLRG (Polish Lymphoma Research Group) study
    Jurczak, W
    Giza, A
    Krochmalczyk, D
    Wegrzyn, J
    Skotnicki, A
    Czyz, J
    Knopczynska-PosLuszny, W
    Hellman, A
    Centkowski, P
    Ceglarek, B
    Warzocha, P
    ANNALS OF ONCOLOGY, 2005, 16 : 170 - 171
  • [46] Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.
    Rummel, Mathias J.
    Niederle, Norbert
    Maschmeyer, Georg
    Banat, Andre G.
    Von Gruenhagen, Ulrich
    Losem, Christoph
    Kofahl-Krause, Dorothea
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Weidmann, Eckhart
    Duerk, Heinz A.
    Ballo, Harald
    Stauch, Martina
    Barth, Juergen
    Hinke, Axel
    Brugger, Wolfram
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Rituximab combined with dexabeam salvage therapy followed by high dose therapy in patients with relapsed or refractory B-NHL: First results of a phase II multicentre study
    Hess, G.
    Flohr, E. T.
    Kirschey, S. K.
    Wolf, H. W.
    Frickhofen, N. F.
    Roesler, W. R.
    Link, H. L.
    Basara, N. B.
    Peter, N. P.
    Schmitz, N. S.
    Weidmann, E. W.
    Banat, A. G. B.
    Schulz, A. S.
    Kolbe, K. K.
    Derigs, G. D.
    Huber, C. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 111 - 111
  • [48] Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL)-7 Year Updated Results from the StiL NHL1 Study
    Rummel, Mathias J.
    Maschmeyer, Georg
    Ganser, Arnold
    Heider, Andrea
    von Gruenhagen, Ulrich
    Losem, Christoph
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Weidmann, Eckhart
    Duerk, Heinz
    Boeck, Hans Peter
    Stauch, Martina Beate
    Barth, Juergen
    Blau, Wolfgang
    Burchardt, Alexander
    Kauff, Frank
    Hinke, Axel
    Brugger, Wolfram
    BLOOD, 2014, 124 (21)
  • [49] Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD plus C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT
    Dubreuil, Julien
    Houot, Roch
    Le Gouill, Steven
    Mounier, Christiane
    Courby, Stephane
    Dartigeas, Caroline
    Bouabdallah, Krimo
    Moles, Marie Pierre
    Magda, Alexis
    Tournilhac, Olivier
    Uribe, Mario Ojeda
    Bourre, Jean Cyril
    Bodet-Milin, Caroline
    Vuillez, Jean-Philippe
    Gressin, Remy
    BLOOD, 2014, 124 (21)
  • [50] Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy A Post Hoc Analysis of a Randomized Clinical Trial
    Mignard, Claire
    Maho-Vaillant, Maud
    Golinski, Marie-Laure
    Balaye, Pierre
    Prost-Squarcioni, Catherine
    Houivet, Estelle
    Calbo, Sebastien
    Labeille, Bruno
    Picard-Dahan, Catherine
    Konstantinou, Maria Polina
    Chaby, Guillaume
    Richard, Marie-Aleth
    Bouaziz, Jean-David
    Duvert-Lehembre, Sophie
    Delaporte, Emmanuel
    Bernard, Philippe
    Caux, Frederic
    Alexandre, Marina
    Ingen-Housz-Oro, Saskia
    Vabres, Pierre
    Quereux, Gaelle
    Dupuy, Alain
    Debarbieux, Sebastien
    Avenel-Audran, Martine
    D'Incan, Michel
    Bedane, Christophe
    Beneton, Nathalie
    Jullien, Denis
    Dupin, Nicolas
    Misery, Laurent
    Machet, Laurent
    Beylot-Barry, Marie
    Dereure, Olivier
    Sassolas, Bruno
    Benichou, Jacques
    Joly, Pascal
    Hebert, Vivien
    JAMA DERMATOLOGY, 2020, 156 (05) : 545 - 552
12345